Wednesday, February 10, 2010, 2:02PM AEST - The Australian Stockmarket closes in 2 hours and 3 minutes.
To create a watchlist or portfolio of shares, Register

Progenics Pharmaceuticals Inc. (PGNX)

8:00AM AEST: 4.51 USD  Up 0.04 (0.89%)  
 MORE ON PGNX 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 Progenics Pharmaceuticals Inc. (NGM:PGNX) Delayed quote dataEdit
Last Trade:4.51 USD
Trade Time: 8:00AM AEST
Change:Up 0.04 (0.89%)
Prev Close:4.47
Open:4.41
Bid:3.74 x 100
Ask:5.15 x 100
1y Target Est:6.50
Day's Range:4.36 - 4.52
52wk Range:3.53 - 9.11
Volume:67,092
Avg Vol (3m):140,195
Market Cap:142.80M
P/E (ttm):N/A
EPS (ttm):-1.47
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
 Add PGNX to Portfolio   Download Data

 HEADLINES 
PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
EDGAR Online (Fri, Feb 5)
Progenics Presents Novel Multiplex PI3-Kinase Inhibitors at American Association for Cancer Research Conference on Protein Translation and Cancer
Business Wire (Fri, Feb 5)
Wyeth Can't Save Pfizer
at Motley Fool (Thu, Feb 4)
UPDATE - Pfizer profit misses; 2010 outlook below Street
at Reuters (Thu, Feb 4)
5 Top Stocks at Half Price
at Motley Fool (Thu, Jan 21)
4-Star Stocks on the Upswing
at Motley Fool (Thu, Nov 19)
PROGENICS PHARMACEUTICALS INC Financials
EDGAR Online Financials (Sat, Nov 14)
PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition
EDGAR Online (Tue, Nov 10)
PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
EDGAR Online (Sat, Oct 17)
Biotech Stock Mailbag: Oncothyreon
at TheStreet.com (Fri, Oct 16)
More Headlines for PGNX...

 ANALYST 
EPS Est (next year) (Dec-09) :-1.12
EPS Est (in 2 years) (Dec-10) :-1.48
Avg Rec (current)*:2.6
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Progenics Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases in the U...

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News7 Indices